]>
IRCT138807192573N1 IRCT 2010-01-16 Medical university of Kurdistan and Maastricht University A Randomized Controlled Trial of Behavioral Activation and Treatment As Usual in the Acute Treatments of Adults with Major Depressive Disorder. A Randomized Controlled Trial of Behavioral Activation and Treatment As Usual in the Acute Treatments of Adults with Major Depressive Disorder. 2009-10-22 anticipated 100 Complete https://irct.ir/trial/2321 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Other, Purpose: Treatment. 2 Major Depressive Disorder. Intervention 1: In behavioral activation group, 16 sessions of BA treatment, for the first month every week two sessions 50 minutes and for the second and third months of the treatment, every week one session will be held. Intervention 2: Sertraline 25 mg daily for the first week, 50 mg for the second and third weeks, 75 mg for the fourth and fifth weeks and 100 mg for the sixth week and until the end of the treatment.
public Latif Moradveisi
Sanandaj
Sanandaj Iran (Islamic Republic of) +98 918 784 8047 latif.moradveisi@maastrichtuniversity.nl Maastricht University scientific Latif Moradveisi
Sanandaj, Medical University of Kurdistan
Sanandaj Iran (Islamic Republic of) +98 87 1728 7047 lmoradveisi@gmail.com Medical University of Kurdistan And Maastricht University Iran (Islamic Republic of) Inclusion criteria : diagnosis of major depression according to the SCID-I, severity above 19 on the BDI and 13 on the HRSD, age 18-70, written consent to participate with the study. Exclusion criteria : if they have a life time diagnosis of bipolar disorder, organic brain syndrome, psychosis or mental retardation. Additional exclusion criteria are: substantial and imminent suicide risk; a current (e.g., within the past six months) or primary diagnosis of alcohol or drug abuse or dependence or a positive toxicology screen; a primary diagnosis of panic disorder, obsessive-compulsive disorder, psychogenic pain disorder, anorexia, or bulimia. In addition, participants who did not respond favorably within the preceeding year to medication will be excluded. Participants who have unstable medical condition and using any medication that would complicate the administration of antidepressant medication (medication in my study), or have a known allergy to medication in this study will be excluded. Moreover, women who are pregnant or maybe want to be pregnant will be excluded. Lastly, participants have to able to read and understand the questionnaires and interviews used in the study. 18 years 70 years Both F32 Depressive episode Behavior Treatment - Drugs In behavioral activation group, 16 sessions of BA treatment, for the first month every week two sessions 50 minutes and for the second and third months of the treatment, every week one session will be held. Sertraline 25 mg daily for the first week, 50 mg for the second and third weeks, 75 mg for the fourth and fifth weeks and 100 mg for the sixth week and until the end of the treatment. Treatment of major depressive disorder. Timepoint: Before intervention, in the middle of Intervention (45 days after starting treatment) and after treament ( after 3 months treatment duration).). Method of measurement: In BA, by BDI-II and In TAU, HRSD is used. Prevention and relapse of major depressive disorder. Timepoint: One year after termination of the treatment. Method of measurement: In BA, by BDI-II and In TAU, HRSD is used. Medical university of Kurdistan and Maastricht University Approved Committee of Medical Ethics, Second Session Medical University of Kurdistan,Ghods Hospital, Ghods Avenue, Pasdaran Street, Sanandaj. Kurdistan. Iran Sanandaj Iran (Islamic Republic of)